N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 3 N=295 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158
Phase 3 N=285 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Phase 3 N=353 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Phase 2 N=9 Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Pruritus
Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale
Phase 3 N=62 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 3 N=151 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…
Phase 2 N=20 Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Prurigo Nodularis · Pruritus · Chronic Pruritus
Primary: Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 — -78.26; -53.66 percent change — p=<0.001
Phase 2 N=10 A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Phase 4 N=72 Treatment of Pruritus With Intramuscular Promethazine
Pruritus · Pregnancy Related
Primary: Does the Addition of Promethazine Reduce Itching After Spinal Morphine for Cesarean Delivery? — 22; 17; 10; 15 Participants
Phase 2 N=204 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Pruritus · Psoriasis
Primary: WI-NRS 4-point Responder Rate at Week 8 — 33.29; 21.07 % of subjects (incl. imputed data)
Phase 2 N=240 Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Prurigo Nodularis · Pruritis
Primary: Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) Score — -50.6; -29.4; -56.2; -51.0 percentage change — p=0.0347
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Phase 3 N=373 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale — -3.10; -3.49; -2.80 units on a scale
Phase 2 N=247 A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 8 of the Treatment Period — -2.97; -3.65; -3.64; -2.86 points — p=0.770
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
Phase 4 N=40 Management of Pruritus With Xyzal in Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale
Phase 2 N=168 Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Atopic Dermatitis
Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale
Phase 2 N=69 Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm
Phase 3 N=130 Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
Psoriasis
Primary: Pruritus Intensity Visual Analogue Scale Score at Week 32 — 8.8; 27.1 Units on a scale — p=0.0055
Phase 2 N=269 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Phase 3 N=175 Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001
Phase 3 N=178 A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 4 — -2.06; -1.09 points — p=<0.001